6.73
-0.01 (-0.15%)
| Penutupan Terdahulu | 6.74 |
| Jumlah Dagangan | 69,802 |
| Harga / Pendapatan (P/E Ke hadapan) | 78.12 |
| Harga / Jualan (P/S) | 6.61 |
| Harga / Buku (P/B) | 6.63 |
| Julat 52 Minggu |
| Margin Keuntungan | 7.20% |
| Margin Operasi (TTM) | 10.31% |
| EPS Cair (TTM) | 0.020 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -18.80% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | -64.20% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1.52% |
| Nisbah Semasa (MRQ) | 3.60 |
| Aliran Tunai Operasi (OCF TTM) | -6.65 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -8.55 M |
| Pulangan Atas Aset (ROA TTM) | 5.18% |
| Pulangan Atas Ekuiti (ROE TTM) | 12.12% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Gyre Therapeutics, Inc. | Bercampur | - |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Purata | 0.00 |
|
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 91.25% |
| % Dimiliki oleh Institusi | 2.99% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Purata Hasil Dividen 4T | 4.73% |
| Tarikh EX | Tarikh Pengumuman | Tarikh Pembayaran | Perincian |
|---|---|---|---|
| 13 Jan 2023 | 26 Dec 2022 | 12 Jan 2023 | 0.24 Tunai |
| 21 Sep 2022 | 24 Aug 2022 | 20 Sep 2022 | 1.43 Tunai |
| 20 Aug 2015 | 04 Aug 2015 | 19 Aug 2015 | 1.6492 Tunai |
Hasil Dividen Tahunan
| Tahun | Dividen Tahunan ($) | Kekerapan/Tahun | Hasil % |
|---|---|---|---|
| 2023 | 0.240 | 1 | 0.93 |
| 2022 | 1.43 | 1 | 17.99 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |